These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
785 related articles for article (PubMed ID: 29921764)
1. Targeting Transcription Factors for Cancer Treatment. Lambert M; Jambon S; Depauw S; David-Cordonnier MH Molecules; 2018 Jun; 23(6):. PubMed ID: 29921764 [TBL] [Abstract][Full Text] [Related]
2. Targeting transcription factors by small compounds--Current strategies and future implications. Hagenbuchner J; Ausserlechner MJ Biochem Pharmacol; 2016 May; 107():1-13. PubMed ID: 26686579 [TBL] [Abstract][Full Text] [Related]
3. Targeting Transcription Factor Binding to DNA by Competing with DNA Binders as an Approach for Controlling Gene Expression. Bouhlel MA; Lambert M; David-Cordonnier MH Curr Top Med Chem; 2015; 15(14):1323-58. PubMed ID: 25866275 [TBL] [Abstract][Full Text] [Related]
4. Targeting General Transcriptional Machinery as a Therapeutic Strategy for Adult T-Cell Leukemia. Wong RWJ; Ishida T; Sanda T Molecules; 2018 May; 23(5):. PubMed ID: 29724031 [TBL] [Abstract][Full Text] [Related]
5. Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View. Dar KB; Bhat AH; Amin S; Anjum S; Reshi BA; Zargar MA; Masood A; Ganie SA Curr Cancer Drug Targets; 2019; 19(6):430-448. PubMed ID: 30073927 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938 [TBL] [Abstract][Full Text] [Related]
7. Perspectives on the discovery of NOTCH2-specific inhibitors. Dobranowski P; Ban F; Contreras-Sanz A; Cherkasov A; Black PC Chem Biol Drug Des; 2018 Mar; 91(3):691-706. PubMed ID: 29078041 [TBL] [Abstract][Full Text] [Related]
13. Phospho-BRD4: transcription plasticity and drug targeting. Chiang CM Drug Discov Today Technol; 2016 Mar; 19():17-22. PubMed ID: 27769352 [TBL] [Abstract][Full Text] [Related]
14. Touch and go: nuclear proteolysis in the regulation of metabolic genes and cancer. Maneix L; Catic A FEBS Lett; 2016 Apr; 590(7):908-23. PubMed ID: 26832397 [TBL] [Abstract][Full Text] [Related]
15. DNA topoisomerase i as a transcription protein and a lethal cellular toxin. Lotito L; Ferri F; Russo A; Capranico G Ital J Biochem; 2007 Jun; 56(2):122-9. PubMed ID: 17722653 [TBL] [Abstract][Full Text] [Related]
16. Targeting the molecular basis for tumour hypoxia. Carroll VA; Ashcroft M Expert Rev Mol Med; 2005 Apr; 7(6):1-16. PubMed ID: 15831177 [TBL] [Abstract][Full Text] [Related]
17. Use of transcription factors as agents and targets for drug development. Smith LM; Birrer MJ Oncology (Williston Park); 1996 Oct; 10(10):1532-8; discussion 1541-2. PubMed ID: 8905845 [TBL] [Abstract][Full Text] [Related]
18. Transcription factors as targets for DNA-interacting drugs. Gniazdowski M; Denny WA; Nelson SM; Czyz M Curr Med Chem; 2003 Jun; 10(11):909-24. PubMed ID: 12678680 [TBL] [Abstract][Full Text] [Related]
19. Chaperome heterogeneity and its implications for cancer study and treatment. Wang T; Rodina A; Dunphy MP; Corben A; Modi S; Guzman ML; Gewirth DT; Chiosis G J Biol Chem; 2019 Feb; 294(6):2162-2179. PubMed ID: 30409908 [TBL] [Abstract][Full Text] [Related]
20. Modulation of gene transcription by natural products--a viable anticancer strategy. D'Incalci M; Brunelli D; Marangon E; Simone M; Tavecchio M; Gescher A; Mantovani R Curr Pharm Des; 2007; 13(27):2744-50. PubMed ID: 17897020 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]